CVVTF (CVVTF)

Recent earnings expectations and fresh store openings have put CVS Health (CVS) in focus for investors. The stock now sits near US$105 after a strong past year, raising questions about what is already reflected in the price. See our latest analysis for CVS Health.

Beyond analysts' top-and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our latest analysis for Veracyte. The earnings beat and higher 2026 revenue guidance have coincided ...

Corteva Inc (CTVA) released its 8-K filing on July 30, 2026, showcasing financial results for the second quarter (Q2) and the first half (1H) of 2026. The compa

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.